Combinations of antibodies selective for a tumor necrosis...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 31/00 (2006.01) A61K 31/337 (2006.01) A61K 31/519 (2006.01) A61K 38/00 (2006.01) A61K 39/00 (2006.01) A61K 41/00 (2006.01) A61K 45/06 (2006.01) A61P 35/00 (2006.01) C07K 16/28 (2006.01)

Patent

CA 2465314

An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.

L'invention porte sur un anticorps ayant une interaction avec le récepteur DR5 ou DR4 humain et générant des effets agonistes ou antagonistes en aval du récepteur, cet anticorps permettant d'inhiber la prolifération cellulaire et l'apoptose. L'invention porte également sur des procédés de production et d'utilisation des anticorps, éventuellement en combinaison avec divers agents thérapeutiques, notamment dans le traitement de maladies relatives à l'apoptose et de la prolifération cellulaire anarchique.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combinations of antibodies selective for a tumor necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combinations of antibodies selective for a tumor necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of antibodies selective for a tumor necrosis... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1576045

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.